000 | 01918 a2200505 4500 | ||
---|---|---|---|
005 | 20250517120544.0 | ||
264 | 0 | _c20170814 | |
008 | 201708s 0 0 eng d | ||
022 | _a1178-2005 | ||
024 | 7 |
_a10.2147/COPD.S115132 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aCheng, Shih-Lung | |
245 | 0 | 0 |
_aEffectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. _h[electronic resource] |
260 |
_bInternational journal of chronic obstructive pulmonary disease _c2016 |
||
300 |
_a2341-2348 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdministration, Inhalation |
650 | 0 | 4 |
_aAdrenal Cortex Hormones _xadministration & dosage |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadministration & dosage |
650 | 0 | 4 |
_aBronchodilator Agents _xadministration & dosage |
650 | 0 | 4 | _aDisease Progression |
650 | 0 | 4 |
_aDrug Monitoring _xmethods |
650 | 0 | 4 |
_aEosinophils _xdrug effects |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFluticasone _xadministration & dosage |
650 | 0 | 4 |
_aFluticasone-Salmeterol Drug Combination _xadministration & dosage |
650 | 0 | 4 | _aForced Expiratory Volume |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aLeukocyte Count |
650 | 0 | 4 |
_aLung _xdrug effects |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aPredictive Value of Tests |
650 | 0 | 4 |
_aPulmonary Disease, Chronic Obstructive _xblood |
650 | 0 | 4 | _aQuality of Life |
650 | 0 | 4 | _aRecovery of Function |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 | _aVital Capacity |
700 | 1 | _aLin, Ching-Hsiung | |
773 | 0 |
_tInternational journal of chronic obstructive pulmonary disease _gvol. 11 _gp. 2341-2348 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.2147/COPD.S115132 _zAvailable from publisher's website |
999 |
_c26484026 _d26484026 |